$AVR

L1 Capital Pty Ltd sold $5.8M of AVR (indirect holdings)

L1 Capital Pty Ltd sold 714,138 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $8.17 ($8.04–$8.20, $5.83M total) across 2 trades over 2026-07-29 to 2026-07-30.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Jul 31, 2026, 10:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 10:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AVR
Neutral
medium confidence
Mentioned
$AVR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRNeutralLow
01

Why it matters

A 10% owner (L1 Capital Pty Ltd) sold $5.83M of AVR shares across two open-market trades at roughly $8.04 to $8.20, with holdings after sale reported at 6,633,314 shares.

02

Market read

Traders may monitor AVR for sentiment effects from a sizable holder sale, but the filing does not introduce new operational or financial catalysts.

03

What to watch

Because the holdings are indirect and the filing lacks stated rationale, traders may over-interpret the signal versus the broader context of the holder’s portfolio and tax/liquidity needs.

Relevance 6/10Novelty 4/10Timing: filed 2026-07-31, covering sales dated 2026-07-29 to 2026-07-30

Background

The article is an SEC Form 4 insider transaction disclosure for Anteris Technologies Global Corp. (AVR).

Company-level read

Ticker impact

$AVRNeutralMedium confidence
Context

L1 Capital Pty Ltd, a 10% owner, sold 714,138 AVR shares in open-market trades at $8.0400 to $8.2000, totaling $5.83M, via indirect holdings.

Expected impact

Near-term impact is likely limited, with any effect more sentiment-driven than fundamental.

Evidence & confidence

Form 4 shows the transaction size and price range, but provides no new company-specific operating or financial information; also notes no 10b5-1 plan.

Market effects

No direct sector read-through; this is company-specific ownership activity.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan does not necessarily imply negative information; sales can be liquidity or diversification-driven.

Key entities

  • Anteris Technologies Global Corp.

    Subject of the Form 4 insider transaction disclosure, ticker AVR.

  • L1 Capital Pty Ltd

    Reporter of the indirect open-market sale of AVR shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVRMedAI 8/10

Small Cap watch: ASX small caps ease after strong week as NewPeak, Orthocell and Anteris advance drilling, sales and data

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

$AVRMedAI 8/10

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day outcomes for its DurAVR THV in 22 patients with medium aortic annuli, showing positive hemodynamic and safety results. The DurAVR THV is being evaluated in the ongoing PARADIGM trial, a global study comparing it to commercially available TAVRs. The company aims to confirm the valve's effectiveness in a randomized setting.

$AVRMedAI 8/10

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

Anteris Technologies (ASX:AVR, NASDAQ:AVR) received German regulatory approval to expand its PARADIGM heart valve trial, allowing patient recruitment in Europe's largest market. The trial aims to enroll 1,000 patients to evaluate the DurAVR valve against existing devices. The company expects Germany's expertise to accelerate enrollment. DurAVR is a transcatheter heart valve designed to mimic a healthy aortic valve.